KRAS and cancer: Considering the wide use of anti-PD-1 antibodies in clinical treatment of multiple solid tumors, future investigations of 1-2C TCR-T cells in combination with anti-PD-1 antibodies may be promising for cancer patients with the KRAS-G12V mutation.